Predicting future cognitive impairment in preclinical Alzheimer's disease using multimodal imaging: a multisite machine learning study

Author information

Braden Yang[1] (0000-0002-2558-4132), Tom Earnest[1] (0000-0001-8671-8424), Murat Bilgel[2*] (0000-0001-5042-7422), Marilyn S. Albert[3] (0000-0002-8167-8985), Sterling C. Johnson[4] (0000-0002-8501-545X), Christos Davatzikos[5] (0000-0002-1025-8561), Guray Erus[5] (0000-0001-6633-4861), Colin L. Masters[6] (0000-0003-3072-7940), Susan M. Resnick[2*] (0000-0003-1115-7145), Michael I. Miller[7] (0000-0003-4689-3855), Arnold Bakker[8,3] (0000-0003-0417-641X), John C. Morris[9] (0000-0001-9820-5618), Tammie L.S. Benzinger[1] (0000-0002-8114-0552), Brian A. Gordon[1] (0000-0003-2109-2955), Aristeidis Sotiras[1,10] (0000-0003-0795-8820), for the Alzheimer's Disease Neuroimaging Initiative[†], for the Preclinical Alzheimer's Disease Consortium

[1] Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA 63110

[2] Laboratory of Behavioral Neuroscience, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD, USA 21224

[3] Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA 21205

[4] Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA 53726

[5] Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI^{2}D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

[6] Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia 3052

[7] Center of Imaging Science and Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA 21218

[8] Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA 21205

[9] Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA 63110

[10] Institute for Informatics, Data Science and Biostatistics, Washington University School of Medicine in St. Louis, St. Louis, MO, USA 63110

Please address all correspondence to: Braden Yang (b.y.yang@wustl.edu), Aristeidis Sotiras (aristeidis.sotiras@wustl.edu)

[*]This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH authors are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.

[†]Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Highlights

- Machine learning can predict future cognitive impairment in preclinical Alzheimer's
- Models achieved high out-of-sample ROC-AUC on external sites and PET tracers
- Models were able to distinguish cognitively stable from decliners in the A4 cohort
- ML cohort enrichment enhanced secondary treatment effect detection in the A4 cohort

Abstract

Predicting the likelihood of developing Alzheimer's disease (AD) dementia in at-risk individuals is important for the design of and optimal recruitment for clinical trials of disease-modifying therapies. Machine learning (ML) has been shown to excel in this task; however, there remains a lack of models developed specifically for the preclinical AD population, who display early signs of abnormal brain amyloidosis but remain cognitively unimpaired. Here, we trained and evaluated ML classifiers to predict whether individuals with preclinical AD will progress to mild cognitive impairment or dementia within multiple fixed time windows, ranging from one to five years. Models were trained on regional imaging features extracted from amyloid positron emission tomography and magnetic resonance imaging pooled across seven independent sites and from two amyloid radiotracers ([^{18}F]-florbetapir and [^{11}C]-Pittsburgh-compound-B). Out-of-sample generalizability was evaluated via a leave-one-site-out and leave-one-tracer-out cross-validation. Classifiers achieved an out-of-sample receiver operating characteristic area-under-the-curve of 0.66 or greater when applied to all except one hold-out sites and 0.72 or greater when applied to each hold-out radiotracer. Additionally, when applying our models in a retroactive cohort enrichment analysis on A4 clinical trial data, we observed increased statistical power of detecting differences in amyloid accumulation between placebo and treatment arms after enrichment by ML stratifications. As emerging investigations of new disease-modifying therapies for AD increasingly focus on asymptomatic, preclinical populations, our findings underscore the potential applicability of ML-based patient stratification for recruiting more homogeneous cohorts and improving statistical power for detecting treatment effects for future clinical trials.

Keywords

preclinical Alzheimer's disease; machine learning; support vector machine; amyloid positron emission tomography; structural magnetic resonance imaging; patient stratification; clinical trial cohort enrichment

1 Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disease marked by the accumulation of amyloid-β plaques and tau neurofibrillary tangles in the brain, which leads to neuronal cell death and eventual development of cognitive deficits. According to current models of the AD pathogenesis timeline, accumulation of these pathologies typically begin years before the onset of clinically-measurable symptoms (Jack and Holtzman, 2013; Jack Jr. et al., 2024). Thus, clinical trials of AD treatments have largely focused on disease-modifying therapies, which target these pathologies in the hopes of altering the biological course of the disease and slowing or even preventing the progression of clinical symptoms (Dyck et al., 2023; Sims et al., 2023). Yet to date, there have only been a handful of approved disease-modifying therapies, with the rest failing to demonstrate a significant treatment effect (Kim et al., 2022). A potential reason for this high failure rate is that recruited participants may have been at too advanced of a disease stage for treatments to meaningfully alter its progression (Sperling et al., 2014), with the majority of previously conducted trials primarily recruiting individuals who already displayed objective cognitive impairment (Huang et al., 2020; Sims et al., 2023; Swanson et al., 2021). In response, newly emerging trials have transitioned to targeting preclinical AD, where patients exhibit abnormal brain amyloidosis while showing no signs of cognitive impairment. Furthermore, failures may have also been attributed to high heterogeneity in the phenotypic expression of the disease, particularly in the rates of cognitive decline over time. This heterogeneity potentially leads to differential responses to administered therapies, which may negatively impact the estimation of treatment effects (Jutten et al., 2021).

To mitigate this issue, stratification models for identifying ideal candidates for clinical trials are commonly employed. These models enable cohort enrichment by identifying and selectively enrolling candidates who are most likely to benefit from disease-modifying therapies in order to increase the likelihood of observing a potential treatment effect (Ballard et al., 2019; Wolz et al., 2016). Additionally, they may aid in reducing uncertainties in null treatment effects by ensuring proper random allocation into treatment and placebo groups, on top of reducing the required sample size and cost of running a trial (Wang et al., 2024). Previous trials have used single risk assessments such as neuropsychological testing and quantitative amyloid and tau measurements from positron emission tomography (PET) to stratify subjects into high and low risk groups (Abdelnour et al., 2022; Sims et al., 2023; Swanson et al., 2021). However, recent evidence has suggested that data-driven stratification models built on machine learning (ML) can outperform single risk factor stratification in enhancing clinical trial operations (Birkenbihl et al., 2024; Gladstein et al., 2025; Nallapu et al., 2025; Tam et al., 2022; Wang et al., 2024). By leveraging information across multiple data modalities such as imaging, genetics and cognitive assessments, ML models can learn complex patterns within these multiple modalities to provide more accurate stratifications. These stratifications may be used to guide a more optimized cohort enrichment, leading to increased power of detect hypothetical treatment effects (Nallapu et al., 2025), reduction in random allocation bias (Wang et al., 2024), and reduction in the sample size required to observe a treatment effect (Birkenbihl et al., 2024; Gladstein et al., 2025; Tam et al., 2022). Among data modalities commonly used for stratification, medical imaging data like PET and magnetic resonance imaging (MRI) are particularly useful for probing the topographical distribution of core and associated AD pathologies in the brain (Jack Jr. et al., 2024), which have been shown to be highly discriminative of cognitive decliners from non-decliners (Mathotaarachchi et al., 2017; Pascoal et al., 2020; Pfeil et al., 2021).

Despite recent progress in developing ML models for this application, previous literature has predominantly focused on subjects who already exhibit cognitive deficits in the form of mild cognitive impairment (MCI) (Ezzati et al., 2021; Samper-González et al., 2018), with many studies only training on features extracted from structural MRI (Basaia et al., 2019; Mathotaarachchi et al., 2017; Misra et al., 2009). Efforts have been made to develop models for the cognitively unimpaired (CU) population that also incorporate amyloid PET, but most have either imposed a single time-to-progression window (Choi et al., 2024; Dansson et al., 2021; Pfeil et al., 2021) or don't ensure the presence of amyloid pathology in their CU cohorts (Karaman et al., 2022). Additionally, with trials routinely involving large consortiums of institutions, each utilizing a different set of data acquisition protocols and scanner models, this introduces site-specific biases in the collected data which may negatively affect the ability of models to generalize on out-of-sample data. Furthermore, disparities in the pharmacokinetics and binding properties of different PET radiotracers lead to significant biases in quantitative amyloid PET measurements (Landau et al., 2014; Su et al., 2019; Villemagne et al., 2012). For these reasons, a rigorous evaluation of ML generalizability to external sites and different amyloid PET radiotracers is needed.

Motivated by these gaps, the current study seeks to develop and evaluate ML classifiers to predict future cognitive decline in asymptomatic, preclinical AD patients. We trained support vector machines (SVM) on regional imaging features extracted from amyloid PET and structural MRI to perform binary classification of whether an individual will develop cognitive deficits within multiple follow-up times, ranging from one year to five years. We obtained data from seven independent sites and two amyloid PET radiotracers and estimated the out-of-sample performance of trained models via leave-one-site-out and leave-one-tracer-out cross-validation. Lastly, to gauge the benefit of applying these models in a clinical trial setting, we utilized data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study (Sperling et al., 2023)

to estimate the change in statistical power to detect treatment effects after retroactive cohort enrichment using our models' predictions.

2 Materials and methods

2.1 Participants and data

Participants and their respective data were obtained from the following independent studies and consortia – the A4 study (Sperling et al., 2023), the Alzheimer's Disease Neuroimaging Initiative (ADNI), the Harvard Aging Brain Study (HABS) (Dagley et al., 2017), the Mayo Clinic Study of Aging (MCSA) (Roberts et al., 2008), the Open Access Series of Imaging Studies 3 (OASIS) (LaMontagne et al., 2019), and the Preclinical Alzheimer's Disease Consortium (PAC). ADNI, launched in 2003 as a public-private partnership and led by Principal Investigator Michael W. Weiner, MD, has aimed to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. PAC is a consortium comprising five AD-focused datasets – the Adult Children Study (ACS) (Coats and Morris, 2005; Price and Morris, 1999), the Australian Imaging Biomarkers and Lifestyle (AIBL) study (Fowler et al., 2021), the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study (Albert et al., 2014), the Baltimore Longitudinal Study of Aging (BLSA) (Resnick et al., 2000), and the Wisconsin Registry for Alzheimer's Prevention (WRAP) (Johnson et al., 2018). All participants provided informed consent to participate in their respective studies in accordance with the Declaration of Helsinki, and ethics approvals were obtained by each site's respective institutional review board. From the A4 study, only participants from the placebo arm of the clinical trial or from the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study were used to train the ML models. Participants from the Solanezumab treatment arm were excluded from training and were only used as an additional evaluation set (detailed in section *2.5 A4 trial analyses*). Additionally, we

omitted ACS from our analyses since this dataset had significant participant overlap with OASIS.

All participants with available [^{18}F]-florbetapir (FBP) or [^{11}C]-Pittsburgh-compound-B (PiB) amyloid PET imaging were selected. We restricted these scans to be amyloid-positive, defined as having a mean cortical amyloid PET signal of greater than a threshold value. We used the dataset-specific definition of the summary cortical region mask and cutoff signal that was optimally determined for each dataset. All scans were matched with an accompanying structural T1-weighted MRI scan and a global Clinical Dementia Rating® (CDR) (Morris, 1997) within one year of the PET acquisition date. Baseline age, sex and *APOE4* carriership were selected as additional predictors. Participants who were missing any matching data were excluded from further analyses. All participants were restricted to be CU within one year of the amyloid PET, defined as a global CDR of zero. We labeled participants as stable if they remained CU for at least five years from the time of the amyloid PET, and as progressor if they converted to a global CDR of greater than zero within a follow-up time that varied from one to five years. Progressors who reverted to CU were excluded. Additionally, stables who did not have a follow-up CDR of zero at least five years from the time of the amyloid PET were excluded. PAC did not provide CDR scores; we instead used the clinical diagnoses in place of CDR, with a diagnosis of either MCI or dementia being equivalent to CDR>0. In total, 343 stable and 247 progressor subjects across seven sites (A4, ADNI, AIBL, BLSA, HABS, MCSA, OASIS) were selected for this study. We excluded BIOCARD and WRAP from our analyses due to too few participants meeting the selection criteria. Subject counts after exclusions are illustrated in Supplementary Fig. 1.

2.2 Image acquisition and processing

All scans underwent a standard PET-MRI processing pipeline consisting of segmentation of the MRI into regions-of-interest (ROI) and derivation of regional amyloid standardized uptake value

ratios (SUVR) from the amyloid PET. Each participant's T1-weighted MRI was preprocessed using a fully automated pipeline which included N4 bias correction (Tustison et al., 2010), skull-stripping, and segmentation into 145 cortical and subcortical ROI using Multi-atlas region Segmentation utilizing Ensembles of registration algorithms and parameters (MUSE) (Doshi et al., 2016). Manual quality checks were performed on the outputs to ensure correctness of segmentations. We selected 125 relevant ROI and extracted their volumes, normalized by the total intracranial volume, to be used as the volumetric input features of our model.

FBP and PiB PET scans were downloaded either in a frame-averaged, smoothed and uniform-resolution format (ADNI only) or as the full dynamic scan (all other datasets). For dynamic scans, we selected frames within the 50-70 minute window post-tracer injection for FBP and the 40-60 minute window for PiB. All frames were realigned to remove patient motion, averaged, and coregistered to the T1 image using FSL FLIRT rigid body registration (Smith et al., 2004). Additionally, we performed an iterative smoothing operation by applying a Gaussian smoothing kernel with progressively increasing full width at half maximum until a target resolution was reached (estimated using AFNI's *3dFWHMx* tool). The target resolution was set to the *3dFWHMx*-estimated resolution of ADNI frame-averaged scans, which was found to be approximately 10mm isotropic. After smoothing, the PET image was converted to an SUVR image by dividing each voxel by the average signal of the left and right cerebellar gray matter regions. Finally, the MRI-to-PET transformation was applied to the anatomical MUSE ROI labels to sample them to native PET space, and regional SUVRs were computed by averaging the SUVR image over each ROI. For ADNI scans, we only performed coregistration to the T1, SUVR image computation and derivation of regional SUVRs. Manual quality checks were performed to ensure correctness of the frame alignment, PET-MRI coregistration and SUVR computation steps. Of the 145 total ROI, we selected 114 cortical and subcortical gray matter

regions to be used as the amyloid input features of our model. The full list of ROIs used in this study are listed in Supplementary Table 1.

2.3 Model training and validation

We trained SVM binary classifiers with linear kernel to predict whether an individual will progress to CDR greater than zero using baseline amyloid PET SUVR, volumetric and non-imaging (i.e., age, sex, *APOE4*) features. Five separate time-to-progression models were trained independently of one another to predict progressor status, with the time window varied between one and five years. For example, the three-year model predicts if an individual will progress to a CDR of greater than zero within three years from baseline. Note that each model was trained using a different set of progressor subjects. However, we used the same set of stable subjects who remained CU for at least five years as the control group in all five models.

We employed a leave-one-site-out and leave-one-tracer-out cross-validation framework, in which data from one site or from one PET tracer were held out for independent testing, while the remaining data were used for training. Along with five times-to-progression, this resulted in 45 total models. All continuous features were z-scored using the standard deviation of only the CU-stable subjects of the training fold, which was shown to enhance separation between linearly separable groups (Linn et al., 2016). A grid search with five-fold cross-validation was conducted using the training fold to determine the optimal value of hyperparameter C, which regulates how strongly misclassifications impact the SVM optimization. We optimized hyperparameter C independently for each of our 45 models. To evaluate model performance on the leave-out test set, the receiver operating characteristic area-under-the-curve (ROC-AUC), accuracy, balanced accuracy, F1 score, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were reported.

To address biases in amyloid PET SUVRs due to the inclusion of multiple tracers, we performed a sensitivity analysis where we harmonized regional SUVRs into regional Centiloids before

inputting as features to the SVM classifier. The Centiloid scale is a method of linearly transforming raw amyloid PET SUVRs into a scale that is standardized across different tracers (Klunk et al., 2015). We utilized the conversion equations that were uniquely calibrated to each site to convert SUVRs to Centiloid, then retrained our models with Centiloids as the amyloid PET features. Equations were only available for A4, ADNI, MCSA and OASIS, so we included only these sites in the sensitivity analysis.

2.4 Feature importance

To derive a measure of the strength of association between each input feature and the progressor class, we computed the covariance-corrected linear SVM weights proposed by Haufe et al. (2014). This approach transforms classifier weights into interpretable estimates of the feature-level association with the progressor class, with high positive values indicating positive association, high negative values indicating negative association, and values close to zero indicating little to no association. For each classifier, we applied this method to estimate importance values of each input feature, and we averaged the values across all 45 classifiers to derive an overall feature importance. Additionally, to gauge how the magnitude of feature importance varies in relation to the time-to-progression, we estimated the slope of the absolute value of feature importance versus time-to-progression via an ordinary least squares linear regression.

2.5 A4 trial analyses

To further validate trained SVM classifiers, we performed three analyses using the extended A4 study cohort as the external testing set. This extended cohort consisted of participants in the placebo arm and participants treated with Solanezumab, an immunoglobulin monoclonal antibody designed to increase amyloid clearance in the brain. Firstly, we applied the classifier trained on all datasets except A4 to classify A4 participants into stables and progressors using imaging acquired during the screening phase of the trial. We then compared the Preclinical

Alzheimer's Cognitive Composite (PACC), a composite score which has been shown to better track early AD-related cognitive changes (Donohue et al., 2014), between predicted stables and progressors. Mirroring previous work (Donohue et al., 2023; Sperling et al., 2023), we fitted a natural cubic spline model on longitudinal PACC scores as the target variable, using continuous time-from-baseline as the independent variable and baseline age, years of education, *APOE4* carriership, PACC test version administered, and baseline FBP SUVR of a cortical composite region as covariates. We then estimated a model-adjusted mean PACC score and 95% confidence interval at the 240-week follow-up point (corresponding to the end of the placebo-controlled study period) and compared the estimates derived for predicted stables versus predicted progressors. This analysis was independently performed within the placebo and Solanezumab arms.

Secondly, we applied the SVM classifications to conduct retroactive enrichment wherein we restricted the cohort to only include predicted progressors. We then tested for treatment effects post-enrichment in the primary endpoint (model-adjusted PACC) and a secondary endpoint (change in amyloid PET SUVR). For the primary endpoint, we fitted the same natural cubic spline model with covariates on the longitudinal PACC scores of the enriched placebo and treatment cohorts. Model-adjusted means and 95% confidence intervals of PACC at the 240-week follow-up point were estimated and compared between placebo and Solanezumab arms. For the secondary endpoint, we computed the change in FBP cortical SUVR from baseline to the 240-week follow-up point and used this metric as the target variable. An analysis of covariance (ANCOVA) was fitted to compare the mean change in SUVR between placebo and Solanezumab arms, controlling for baseline age, *APOE4* carriership and baseline SUVR as covariates.

Lastly, we performed a bootstrap analysis to estimate the statistical power of detecting a difference in the change in FBP cortical SUVR between baseline and 240-weeks, testing

different sample sizes and sampling populations (i.e. enriched vs. unenriched). Here, we focused only on the secondary endpoint rather than the PACC primary endpoint since no statistically significant treatment effect was reported for the primary endpoint in the original A4 study. For a fixed sample size n, we randomly selected n subjects each from the placebo and Solanezumab arms. The pool of participants to select from was either the full, unenriched cohort or the ML-enriched cohort. We then reran the ANCOVA as conducted previously to test for significant differences in the adjusted change in SUVR between the randomly selected cohorts. We repeated this procedure 1000 times. Power was estimated as the percentage of significant findings across all 1000 iterations. Samples sizes per trial cohort were varied from 10 to 80 in increments of 10.

2.6 Statistical analysis

To compare cohort characteristics, a two-sample t-test was used for all continuous variables, and Fisher's exact test was used for all categorical variables. In the Centiloid sensitivity analysis, the DeLong test was used to compare ROC-AUC between models utilizing harmonized versus unharmonized amyloid PET features. In the A4 trial analyses, a two-sample t-test was performed to compare model-adjusted PACC, and an ANCOVA was performed to compare change in FBP cortical SUVR. In all cases, the significance level was set to $\alpha = 0.05$. When multiple comparisons were made, the Bonferroni correction was applied to adjust p-values.

3 Results

3.1 Cohort characteristics

Table 1 summarizes the cohort characteristics of each site and of the pooled data. Across all sites, progressors were older on average (75.9 ± 6.4) than stables (72.4 ± 5.6, $p < 0.001$) and displayed similar proportions of females-to-males and *APOE4* carriers-to-noncarriers compared

to stables ($p > 0.05$). Progressors had a mean time to progression of 2.4 ± 1.3 years and stables remained CU for an average of 7.1 ± 1.6 years. Stables were scanned with a roughly equal proportion of FBP to PiB radiotracer, whereas progressors were more often scanned with FBP (60%). Within individual sites, only age in the A4 cohort displayed a statistically significant difference between stables and progressors across all demographics reported ($p < 0.001$).

3.2 Model evaluation

Table 1. Cohort characteristics of stables and progressors from all individual sites and the pooled dataset.

	A4		ADNI		AIBL		BLSA		HABS		MCSA		OASIS		pooled	
	stable	**progressor**	**stable**	**progressor**	**stable**	**progressor**	**stable**	**progressor**	**stable**	**progressor**	**stable**	**progressor**	**stable**	**progressor**	**stable**	**progressor**
number of subjects	128	111	22	29	28	14	13	11	4	15	94	43	54	24	343	247
age, mean (SD)	70.05 (3.47)	73.47 (5.17)**	74.25 (6.79)	78.14 (6.00)	72.14 (5.78)	74.23 (6.83)	77.08 (7.04)	83.01 (4.77)	75.56 (1.66)	76.28 (5.33)	75.43 (5.34)	79.19 (7.09)	70.75 (6.17)	75.91 (6.68)	72.41 (5.62)	75.89 (6.43)**
female, count (%)	91 (71)	63 (57)	13 (59)	18 (62)	13 (46)	5 (36)	6 (46)	3 (27)	1 (25)	13 (87)	45 (48)	20 (47)	38 (70)	11 (46)	207 (60)	133 (54)
APOE4 carriership, count (%)	78 (61)	63 (57)	6 (27)	11 (38)	12 (43)	10 (71)	2 (15)	5 (45)	2 (50)	9 (60)	38 (40)	26 (60)	29 (54)	12 (50)	167 (49)	136 (55)
amyloid PET tracer, count (%)																
FBP	128 (100)	111 (100)	22 (100)	29 (100)	-	-	-	-	-	-	-	-	20 (37)	10 (42)	170 (50)	150 (61)
PIB	-	-	-	-	28 (100)	14 (100)	13 (100)	11 (100)	4 (100)	15 (100)	94 (100)	43 (100)	34 (63)	14 (58)	173 (50)	97 (39)
years to CDR>0 progression, mean (SD)	-	2.35 (1.23)	-	2.37 (1.26)	-	3.04 (1.37)	-	2.99 (1.34)	-	2.75 (1.54)	-	2.27 (1.05)	-	2.42 (1.49)	-	2.44 (1.27)
years of CU-stable, mean (SD)	6.68 (0.90)	-	7.55 (1.74)	-	8.68 (2.50)	-	7.31 (2.21)	-	5.38 (0.32)	-	6.84 (1.31)	-	7.61 (1.97)	-	7.10 (1.61)	-
years to CDR>0 progression, count (%)																
0-1 year	-	5 (4.5)	-	6 (21)	-	-	-	-	-	3 (20)	-	4 (9.3)	-	7 (29)	-	25 (10)
1-2 years	-	37 (33)	-	6 (21)	-	4 (29)	-	4 (36)	-	4 (27)	-	13 (30)	-	2 (8.3)	-	70 (28)
2-3 years	-	33 (30)	-	8 (28)	-	2 (14)	-	1 (9.1)	-	1 (6.7)	-	17 (40)	-	8 (33)	-	70 (28)
3-4 years	-	20 (18)	-	4 (14)	-	3 (21)	-	2 (18)	-	4 (27)	-	8 (19)	-	2 (8.3)	-	43 (17)
4-5 years	-	16 (14)	-	5 (17)	-	5 (36)	-	4 (36)	-	3 (20)	-	1 (2.3)	-	5 (21)	-	39 (16)

*$p < 0.05$
**$p < 0.01$
***$p < 0.001$

We evaluated the external site generalizability of the SVM classifier using leave-one-site-out cross-validation. The classifier generalized well to most leave-out sites and times-to-progression, achieving an ROC-AUC of 0.66 or greater, with a majority exceeding 0.75 or above (Figure 1, Table 2). The exception was HABS, for which the ROC-AUC fell below 0.50. We also computed aggregate binary classification metrics by combining the out-of-sample predictions of every model on their respective leave-out site and comparing them to the combined ground truth labels from all sites (Table 2). Classifiers achieved an aggregate accuracy of >0.69 and balanced accuracy of >0.58. Classifiers were also highly specific (>0.74) and had high negative

Figure 1. Receiver operating characteristic curves of SVM classifiers trained on each of five times-to-progression. Curves were obtained by applying each trained model to data from its respective hold-out group. Solid lines represent leave-out sites and dotted lines represent leave-out tracers. Across all times-to-progression, SVM classifiers achieved area-under-the-curve of 0.66 or greater in all leave-out sites except for HABS and 0.72 or greater in both leave-out tracers.



predictive value (>0.74). While models also achieved relatively high sensitivity, PPV and F1 score, these metrics were particularly sensitive to time-to-progression. Notably, smaller times-to-progression resulted in poorer sensitivity, PPV and F1 score, likely due to the fact that classifiers were trained on a fewer number of positive cases and were prone to overfitting to the control cases. Classifiers trained on higher times-to-progression exhibited a better balance between sensitivity/PPV to specificity/NPV.

We additionally performed leave-one-tracer-out validation to assess the generalizability of the SVM classifier to unseen tracers. The classifier achieved ROC-AUC of >0.72 across all times-to-progression for both leave-out tracers (Table 2). However, the model trained on PiB and tested on FBP had a low sensitivity and high specificity while the opposite was true for the model trained on FBP and tested on PiB. This may reflect bias in regional SUVRs between FBP and PiB tracers. To address this, we retrained the classifiers using Centiloid-harmonized regional amyloid PET SUVRs and reported the resulting changes in performance (Supplementary Table 2). After harmonization, models achieved a better balance of sensitivity to specificity for both leave-out tracers: sensitivity increased when testing on FBP, and specificity increased when testing on PiB. This was also accompanied by increased aggregate

balanced accuracy across all times-to-progression. ROC-AUC was slightly decreased in some cases, but none of these changes were statistically significant via the DeLong test ($p > 0.05$).

Table 2. Evaluation metrics of SVM classifiers of all five times-to-progression, tested on each site and tracer as the independent testing set.

		leave-out site/tracer										
	progression time-horizon (yrs)	**A4**	**ADNI**	**AIBL**	**BLSA**	**HABS**	**MCSA**	**OASIS**	**aggregated (site)**	**FBP**	**PIB**	**aggregated (tracer)**
Receiver Operating Characteristic Area-under-the-curve (ROC-AUC)	1	0.8062	0.8030	-	-	0.2500	0.8298	0.9074	-	0.7235	0.8282	-
	2	0.7487	0.7576	1.000	0.7500	0.2143	0.8004	0.9630	-	0.7897	0.8352	-
	3	0.7230	0.8364	0.9881	0.6615	0.3750	0.7078	0.8758	-	0.7537	0.7918	-
	4	0.7573	0.8049	0.9603	0.7473	0.4583	0.7538	0.8489	-	0.7647	0.7679	-
	5	0.7478	0.7743	0.8622	0.7902	0.5000	0.7640	0.8395	-	0.7569	0.7904	-
Accuracy	1	0.8872	0.8214	0.9286	0.5385	0.2857	0.6837	0.9016	0.8098	0.9239	0.6630	0.7935
	2	0.7941	0.7353	0.8125	0.5294	0.2727	0.6126	0.8571	0.7306	0.7807	0.6095	0.6986
	3	0.6897	0.8095	0.8235	0.5000	0.5000	0.6719	0.8310	0.7126	0.6960	0.6553	0.6772
	4	0.7265	0.7826	0.8108	0.6000	0.5000	0.6471	0.8082	0.7169	0.6835	0.6102	0.6497
	5	0.7155	0.7451	0.7619	0.6667	0.5263	0.6204	0.7692	0.6983	0.6469	0.6407	0.6441
Balanced Accuracy	1	0.6531	0.5833	0.9286	0.5385	0.2500	0.7154	0.6336	0.5827	0.5328	0.6931	0.5925
	2	0.6953	0.7197	0.8929	0.6923	0.3214	0.6990	0.8704	0.6948	0.6144	0.7205	0.6325
	3	0.6601	0.8114	0.8929	0.5308	0.5000	0.6264	0.7881	0.6865	0.6162	0.7038	0.6273
	4	0.7061	0.7822	0.8373	0.6593	0.5000	0.6722	0.7510	0.7045	0.6419	0.6810	0.6316
	5	0.7051	0.7429	0.7500	0.6853	0.5167	0.6540	0.7176	0.6901	0.6280	0.6812	0.6270
F1 Score	1	0.2105	0.2857	-	-	0	0.1622	0.4000	0.1860	0.1250	0.2051	0.1915
	2	0.5455	0.6400	0.5714	0.5000	0.2000	0.3944	0.6400	0.5042	0.3902	0.4459	0.4261
	3	0.5655	0.8095	0.6667	0.4000	0.5714	0.4615	0.6667	0.5805	0.4196	0.5525	0.4938
	4	0.6391	0.7917	0.6957	0.6000	0.6000	0.5636	0.6316	0.6355	0.4891	0.5892	0.5459
	5	0.6458	0.7719	0.6667	0.7143	0.6400	0.5517	0.6087	0.6397	0.4645	0.6226	0.5513
Sensitivity	1	0.4000	0.1667	-	-	0	0.7500	0.2857	0.3200	0.0714	0.7273	0.3600
	2	0.5000	0.6667	1.000	1.000	0.1429	0.8235	0.8889	0.6316	0.2759	0.8919	0.5158
	3	0.5467	0.8500	1.000	0.6000	0.5000	0.5294	0.7059	0.6121	0.2913	0.8065	0.4848
	4	0.5684	0.7917	0.8889	0.8571	0.5000	0.7381	0.6316	0.6538	0.3543	0.8765	0.5577
	5	0.5586	0.7586	0.7143	0.9091	0.5333	0.7442	0.5833	0.6397	0.3267	0.8247	0.5223
Specificity	1	0.9062	1.000	0.9286	0.5385	0.5000	0.6809	0.9815	0.8455	0.9941	0.6590	0.8251
	2	0.8906	0.7727	0.7857	0.3846	0.5000	0.5745	0.8519	0.7580	0.9529	0.5491	0.7493
	3	0.7734	0.7727	0.7857	0.4615	0.5000	0.7234	0.8704	0.7609	0.9412	0.6012	0.7697
	4	0.8438	0.7727	0.7857	0.4615	0.5000	0.6064	0.8704	0.7551	0.9294	0.4855	0.7055
	5	0.8516	0.7273	0.7857	0.4615	0.5000	0.5638	0.8519	0.7405	0.9294	0.5376	0.7318
Positive Predictive Value (PPV)	1	0.1429	1.000	-	-	0	0.0909	0.6667	0.1311	0.5000	0.1194	0.1304
	2	0.6000	0.6154	0.4000	0.3333	0.3333	0.2593	0.5000	0.4196	0.6667	0.2973	0.3630
	3	0.5857	0.7727	0.5000	0.3000	0.6667	0.4091	0.6316	0.5519	0.7500	0.4202	0.5031
	4	0.7297	0.7917	0.5714	0.4615	0.7500	0.4559	0.6316	0.6182	0.7895	0.4438	0.5346
	5	0.7654	0.7857	0.6250	0.5882	0.8000	0.4384	0.6364	0.6397	0.8033	0.5000	0.5837
Negative Predictive Value (NPV)	1	0.9748	0.8148	1.000	1.000	0.4000	0.9846	0.9138	0.9446	0.9286	0.9744	0.9465
	2	0.8444	0.8095	1.000	1.000	0.2500	0.9474	0.9787	0.8814	0.7941	0.9596	0.8482
	3	0.7444	0.8500	1.000	0.7500	0.3333	0.8095	0.9038	0.8031	0.6867	0.8966	0.7564
	4	0.7248	0.7727	0.9565	0.8571	0.2500	0.8382	0.8704	0.7825	0.6583	0.8936	0.7246
	5	0.6899	0.6957	0.8462	0.8571	0.2222	0.8281	0.8214	0.7405	0.6100	0.8455	0.6802

3.3 Feature importance

The average importance of each input feature across all trained models is visualized in Figure 2 and Supplementary Fig. 2. For amyloid SUVR features, widespread contributions for predicting the progressor class were observed throughout the cortex, with bilateral inferior and middle temporal gyri exhibiting the strongest mean importance, followed by middle frontal, superior

Figure 2. Covariance-corrected linear SVM weights per amyloid SUVR (top), volumetric (bottom), and non-imaging (right) feature. The values shown are the mean importance across all 45 trained models. The ten features with the highest magnitude of mean importance within each imaging modality are shown on the left. Among amyloid SUVR features, temporal, middle & superior frontal and middle occipital gyri had the highest magnitude mean importance. Among volumetric features, lateral ventricle, hippocampus and amygdala had the highest magnitude mean importance. Age was the only non-imaging feature with a high mean importance.



frontal and middle occipital gyri. In contrast, subcortical amyloid SUVR generally had much lower importance. For volumetric features, bilateral inferior lateral ventricular volumes had the highest absolute value of feature importance out of all features (including amyloid SUVR and non-imaging variables). This was followed by lateral ventricle, amygdala and hippocampus volume. Ventricular volumes all had positive importance values, whereas all other volumetric features had negative importances. Among the three non-imaging features, baseline age was most strongly associated with the progressor class. Neither sex nor *APOE4* carriership showed strong associations.

We also estimated the rate-of-change of the absolute value of feature importance versus the time-to-progression via a linear regression (Supplementary Fig. 3 & 4). For amyloid SUVR features, regions in the orbitofrontal, temporal and occipital cortices had the highest rate of increase in importance as the time-to-progression window grew. Among volumetric regions, the right lateral inferior ventricles, right frontal operculum and bilateral posterior cingulate gyri had

the highest rate of increase. Age had a modest rate of increase, while sex and *APOE4* did not show substantial change. Amyloid SUVR features displayed much greater rates-of-change in feature importance compared to either volumetric features or non-imaging features, suggesting that their influence on model outputs becomes more pronounced as the time-to-progression window expands to capture earlier disease progression.

3.4 A4 trial analysis

We conducted retroactive analyses on the A4 clinical trial dataset to further validate our SVM

classifiers and demonstrate their potential benefit for clinical trial cohort enrichment. Table 3

Table 3. Cohort characteristics of the placebo and Solanezumab treatment arms of the A4 study. The original, unenriched cohort and ML-enriched cohorts are shown.

	cohort					
	original cohort	**1-year progressor**	**2-year progressor**	**3-year progressor**	**4-year progressor**	**5-year progressor**
Placebo						
number of subjects	444	72	132	158	149	150
subjects with FBP PET at 240-week follow-up, count (%)	325 (73)	43 (60)	79 (60)	108 (68)	94 (63)	95 (63)
baseline age, mean (SD)	72.0 (5.0)	75.2 (5.5)***	75.3 (5.2)***	74.6 (5.4)***	75.2 (5.2)***	74.9 (5.3)***
female, count (%)	270 (61)	25 (35)**	60 (45)	86 (54)	74 (50)	78 (52)
APOE4 carriership, count (%)	253 (57)	46 (64)	78 (59)	90 (57)	85 (57)	87 (58)
baseline cortical FBP SUVR, mean (SD)	1.36 (0.17)	1.47 (0.20)**	1.49 (0.18)***	1.46 (0.18)***	1.48 (0.18)***	1.49 (0.18)***
baseline PACC, mean (SD)	0.0 (2.6)	-1.5 (3.1)*	-1.5 (2.9)***	-1.0 (3.1)	-1.3 (2.9)***	-1.2 (3.0)**
annualized PACC rate-of-change, mean (SD)	-0.25 (1.24)	-0.48 (1.44)	-0.49 (1.51)	-0.49 (1.28)	-0.48 (1.45)	-0.48 (1.40)
Solanezumab						
number of subjects	404	61	110	140	150	143
subjects with FBP PET at 240-week follow-up, count (%)	305 (75)	41 (67)	74 (67)	103 (74)	107 (71)	100 (70)
baseline age, mean (SD)	72.2 (4.5)	74.6 (5.1)*	75.1 (4.4)***	74.3 (4.6)***	74.5 (4.5)***	74.6 (4.5)***
female, count (%)	227 (56)	18 (30)**	56 (51)	74 (53)	75 (50)	71 (50)
APOE4 carriership, count (%)	254 (63)	39 (64)	71 (65)	93 (66)	98 (65)	90 (63)
baseline cortical FBP SUVR, mean (SD)	1.37 (0.16)	1.44 (0.17)	1.51 (0.17)***	1.46 (0.18)***	1.48 (0.17)***	1.49 (0.17)***
baseline PACC, mean (SD)	0.05 (2.77)	-1.53 (2.89)**	-1.25 (2.57)***	-0.96 (2.83)*	-1.01 (2.79)**	-1.11 (2.74)**
annualized PACC rate-of-change, mean (SD)	-0.31 (1.17)	-0.76 (1.43)	-0.78 (1.48)	-0.71 (1.37)	-0.69 (1.40)	-0.73 (1.45)

$^{*}p < 0.05$
$^{**}p < 0.01$
$^{***}p < 0.001$

summarizes the characteristics of the unenriched A4 cohort and the retroactively enriched

379 cohorts using each of our five time-to-progression models. In both placebo and Solanezumab

Figure 3. Natural cubic spline models of longitudinal PACC scores of predicted stables and progressors from the A4 study cohort. The model-adjusted PACC trajectory and 95% confidence interval are shown for predicted stables (blue), predicted progressors (red), and the overall cohort (black). The vertical dotted line marks the 240-week follow-up point. The effect size of the contrast between stables and progressors and corresponding p-value are also displayed. Asterisks indicate the significance level (*: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$). In all cases except for the 1-year progressors of the Solanezumab arm, significant differences were observed between stables and progressors in the model-adjusted PACC at 240-weeks.



arms, significant differences between the unenriched and enriched cohorts were observed in baseline age, baseline cortical FBP SUVR (except for the one-year progressors of the Solanezumab arm) and baseline PACC (except for the three-year progressors of the placebo arm) ($p < 0.05$). A lower percentage of females were selected for the enriched cohort in both trial arms compared to the unenriched cohort; this difference was only significant for the one-

Table 4. Comparisons of A4 trial outcomes between placebo and Solanezumab arms of the original, unenriched cohort and the ML-enriched cohorts.

cohort	clinical trial arm	n	model-adjusted estimate at 240-weeks (± SE)	lower 95% CI	upper 95% CI	effect size (± SE)	p-value (Bonferroni corrected)
PACC enrichment analysis							
original cohort	Placebo	444	-1.7 ± 0.217	-2.129	-1.278		
	Solanezumab	404	-2.01 ± 0.273	-2.545	-1.472		
	Contrast	848	-0.305 ± 0.318	-0.9287	0.3188	-0.106 ± 0.111	>0.99
1-year progressor	Placebo	72	-4.86 ± 0.654	-6.153	-3.575		
	Solanezumab	61	-5.35 ± 0.921	-7.163	-3.532		
	Contrast	133	-0.484 ± 1.02	-2.483	1.516	-0.143 ± 0.302	>0.99
2-year progressor	Placebo	132	-5.07 ± 0.5	-6.052	-4.086		
	Solanezumab	110	-5.64 ± 0.671	-6.956	-4.316		
	Contrast	242	-0.567 ± 0.768	-2.073	0.9391	-0.183 ± 0.249	>0.99
3-year progressor	Placebo	158	-4.13 ± 0.443	-4.995	-3.258		
	Solanezumab	140	-4.94 ± 0.559	-6.033	-3.840		
	Contrast	298	-0.81 ± 0.642	-2.069	0.4485	-0.254 ± 0.201	>0.99
4-year progressor	Placebo	149	-4.59 ± 0.452	-5.480	-3.701		
	Solanezumab	150	-4.94 ± 0.546	-6.020	-3.867		
	Contrast	299	-0.354 ± 0.644	-1.616	0.9089	-0.112 ± 0.204	>0.99
5-year progressor	Placebo	150	-4.45 ± 0.456	-5.344	-3.553		
	Solanezumab	143	-5.11 ± 0.583	-6.255	-3.964		
	Contrast	293	-0.661 ± 0.672	-1.978	0.6565	-0.208 ± 0.211	>0.99
Amyloid PET SUVR enrichment analysis							
original cohort	Placebo	325	0.114 ± 0.00623	0.1014	0.1258		
	Solanezumab	305	0.0684 ± 0.00652	0.05565	0.08124		
	Contrast	630	-0.0452 ± 0.00887	-0.06253	-0.02778	-0.407 ± 0.0808	<0.001***
1-year progressor	Placebo	43	0.0961 ± 0.02	0.05629	0.1360		
	Solanezumab	41	0.0453 ± 0.0209	0.003791	0.08681		
	Contrast	84	-0.0508 ± 0.0276	-0.1050	0.003266	-0.407 ± 0.224	0.42
2-year progressor	Placebo	79	0.0804 ± 0.0147	0.05142	0.1094		
	Solanezumab	74	0.0156 ± 0.0149	-0.01383	0.04502		
	Contrast	153	-0.0648 ± 0.0201	-0.1043	-0.02535	-0.523 ± 0.165	0.009**
3-year progressor	Placebo	108	0.089 ± 0.0116	0.06612	0.1119		
	Solanezumab	103	0.044 ± 0.0121	0.02016	0.06780		
	Contrast	211	-0.045 ± 0.0164	-0.07713	-0.01291	-0.379 ± 0.139	0.04*
4-year progressor	Placebo	94	0.0782 ± 0.013	0.05267	0.1038		
	Solanezumab	107	0.0215 ± 0.0123	-0.002737	0.04579		
	Contrast	201	-0.0567 ± 0.0173	-0.09064	-0.02278	-0.464 ± 0.143	0.007**
5-year progressor	Placebo	95	0.076 ± 0.0131	0.05015	0.1018		
	Solanezumab	100	0.0175 ± 0.0128	-0.007682	0.04272		
	Contrast	195	-0.0585 ± 0.0178	-0.09328	-0.02367	-0.473 ± 0.146	0.007**

*$p < 0.05$
**$p < 0.01$
***$p < 0.001$

year progressors ($p < 0.01$). No significant differences were observed in *APOE4* carriership or annualized PACC rate-of-change ($p > 0.05$).

To validate that the SVM classifier accurately distinguish cognitive stables from decliners, we fitted a natural cubic spline model to longitudinal PACC scores of predicted stables and progressors and estimated the model-adjusted mean PACC score at the 240-week follow-up. In

Figure 4. Power to detect differences in change in FBP cortical SUVR between placebo and Solanezumab arms of the A4 study cohort, estimated by bootstrap analysis. Power before (black) and after (colored) retroactive cohort enrichment using SVM classifier predictions are shown. Cohort enrichment by the two-year, four-year and five-year models resulted in increased power at most sample sizes compared to the original, unenriched cohort.



all cases except for the one-year progressor model in the Solanezumab arm, predicted stables had a significantly higher mean estimate of the model-adjusted PACC score at 240 weeks than predicted progressors ($p < 0.01$) (Figure 3, Supplementary Table 3). When using the five-year model, which roughly aligns with the duration of the placebo-controlled period of the A4 trial, predicted progressors of the Solanezumab arm had a mean adjusted PACC score of -3.92 ± 0.57, which was significantly worse ($p < 0.001$) than -0.84 ± 0.26 for predicted stables (Supplementary Table 3). Similarly, in the placebo group, predicted progressors had a mean adjusted PACC score of -3.39 ± 0.43 compared to -0.96 ± 0.22 for predicted stables ($p < 0.001$).

To assess whether cohort enrichment by the trained classifiers improves our ability to detect treatment effects, we tested for significant effects in the primary (PACC) and secondary (FBP cortical SUVR) endpoints after retroactive enrichment. For PACC, we observed no significant difference in the model-adjusted mean PACC score between placebo and Solanezumab arms

when the A4 cohort remained unenriched (Table 4), consistent with the conclusions of the original A4 study (Sperling et al., 2023). The difference in model-adjusted mean PACC remained non-significant after enrichment by any model (Table 4), indicating no clear benefit of retroactive enrichment for recovering an underlying treatment effect in the primary outcome.

For FBP cortical SUVR, a significant difference between trial arms was observed in the mean change in SUVR of the unenriched cohort, with a mean effect size of -0.407 ± 0.08 ($p < 0.001$) (Table 4), suggesting that a reduction in the rate of amyloid accumulation was associated with the treatment. After enrichment, this significant difference was preserved in all but the one-year progressor model. Enrichment by the two, four and five-year models resulted in a modest increase in the mean effect size of the contrast, albeit with an increase in the standard error due to reduced sample sizes. Power analysis revealed that for sample sizes between 20 and 80, an increased power to detect this effect was observed after enrichment by the two, four and five-year models (Figure 4, Supplementary Fig. 5). However, enrichment by the one-year model and, paradoxically, the three-year model showed a decrease in power. This pattern aligned with the results of the ANCOVA in Table 4, wherein mean effect size was increased after enrichment by the two, four and five-year models, but not the one or three-year models.

4 Discussion

We conducted a rigorous evaluation of machine learning classifiers to predict future cognitive impairment among individuals with preclinical Alzheimer's disease using multimodal imaging features from amyloid PET and MRI. Prior studies have demonstrated the ability of ML to predict future dementia in MCI (Ezzati et al., 2021; Grueso and Viejo-Sobera, 2021) and CU (Choi et al., 2024; Dansson et al., 2021; Karaman et al., 2022) individuals with state-of-the-art accuracy. However, unlike previous literature, we restricted our cohort of interest to CU individuals who show evidence of abnormal brain amyloidosis, which has been proposed as a core criterion for the biological definition of AD (Jack Jr. et al., 2024). Additionally, through rigorous leave-one-

site-out and leave-one-tracer-out cross-validation, we demonstrated that these models consistently achieved strong generalizability to unseen sites and amyloid radiotracers. Given that many ongoing and future investigations of disease-modifying therapies for AD are trending towards targeting the preclinical population, the present study represents an important and clinically relevant step towards developing and validating stratification models that are directly tailored to this population. Furthermore, we envision, on the premise that newly emerging treatments intended for asymptomatic preclinical AD patients are approved in the future, that predictive models such as ours would also serve as valuable prognostic tools for guiding individualized treatment plans.

While the global amyloid PET signal has been known to be associated with future cognitive decline (Landau et al., 2018; Parent et al., 2023; Small et al., 2012), recent studies have suggested that regional patterns of amyloid accumulation may serve as a more sensitive marker for the risk of cognitive decline, particularly for preclinical AD (Pascoal et al., 2020; Pfeil et al., 2021). By leveraging amyloid PET biomarkers at the regional level, our models were able to discern spatial patterns which discriminate stables from progressors in the preclinical stage. Among the most important amyloid SUVR features were the temporal, superior and middle frontal, and middle occipital cortices. Many of these regions were previously identified as important correlates to increased risk of cognitive decline (Pascoal et al., 2020; Pfeil et al., 2021). Notably, these regions comprise the intermediate stage of amyloid accumulation according to PET staging models (Mattsson et al., 2019). In contrast, our models assigned a lower average feature importance to regions comprising the early accumulation stage, such as the precuneus and orbitofrontal cortices, suggesting that past a global amyloid threshold, the intermediate stage regions become more important for discriminating future cognitive decline. In terms of MRI features, lateral ventricular volume and the volumes of select subcortical regions such as the hippocampus and amygdala had the highest feature importance. Atrophy in these

regions has consistently been identified as robust markers of AD disease progression (Laakso et al., 1995; Mungas et al., 2002; Nestor et al., 2008). We also found that the importance of amyloid SUVR features increased at a higher rate than volumetric features as the time-to-progression was extended, suggesting that the influence of amyloid PET on model predictions becomes increasingly important as the cohort includes more early-stage progressors. This aligns with current models of AD pathogenesis (Jack Jr. et al., 2024) where amyloid is expected to rise to abnormality well before neurodegeneration occurs, and thus may serve as a better indicator of future cognitive decline in the earlier stages of the disease.

With future clinical trials consisting of multiple institutions, each involving their own unique data acquisition protocols (e.g. scanner models used, scan acquisition protocols, PET radiotracer used, etc.), it is imperative that ML stratification models are robust to any site-specific or tracer-specific biases in the input data. Our SVM classifiers consistently achieved an ROC-AUC of 0.66 or greater for most leave-out sites, demonstrating good out-of-sample generalizability. The notable exception to this was HABS, which scored an ROC-AUC below 0.5. HABS particularly suffered from low sample sizes and extreme imbalances in the stables-to-progressors ratio, leading to high sampling variability which potentially accentuated any existing site-specific biases which the model may not have been robust to. Additionally, models trained on a single amyloid radiotracer achieved ROC-AUC of 0.72 or greater when applied to the other tracer, even when no explicit tracer harmonization was performed. This, along with previous studies which have shown ML models to accurately predict amyloid positivity (Fan et al., 2024) or future cognitive decline (Choi et al., 2024) without explicit harmonization, may suggest that ML models are capable of finding low-dimensional representations of high-dimensional PET data which are tracer-agnostic. However, we also observed that in the context of a binary classification task, the cutoff thresholds (i.e. the separating hyperplane of the linear SVM) used to determine a binary class decision may not generalize to out-of-sample tracers, as evidenced by high

imbalances in the sensitivity and specificity. Converting regional amyloid SUVRs into Centiloids produced models that achieved a much better balance of these metrics, suggesting that explicit harmonization of amyloid PET measurements still holds value for ML models.

In the context of cohort recruitment for clinical trials, the clinical presentation of AD may remain highly heterogeneous even after stratification by single risk factors such as global amyloid PET signal or *APOE4* genotype. Alternatively, ML stratification models trained on a combination of multimodal risk factors have been shown to produce more accurate forecasts of longitudinal cognitive decline, leading to greater enhancements in clinical trial operations (Wang et al., 2024). We successfully identified two distinct subtypes within A4 trial participants that exhibited different rates of cognitive decline, where predicted progressors experienced a significantly faster rate of decline compared to stables. However, when applied to cohort enrichment, our models failed to demonstrate a measurable benefit for enhancing the treatment effect in the primary cognitive outcome, PACC. This could be attributed to a true lack of an underlying treatment effect of Solanezumab therapy. Nonetheless, assuming the presence of a ground-truth drug effect, ML models may still provide a boost in treatment effect detection as evidenced by previous literature (Birkenbihl et al., 2024; Nallapu et al., 2025; Tam et al., 2022). Interestingly, in terms of the secondary outcome, cortical amyloid deposition, the two, four and five-year classifiers identified enriched cohorts that resulted in an increased power for detecting differences in longitudinal amyloid accumulation. However, this was not the case for either the one-year model, likely due to insufficient sample size selected, or the three-year model, perhaps due to selection of a more heterogeneous cohort that consisted of slightly younger participants with slightly lower cortical SUVRs compared to other enriched cohorts. Given these contradictory findings and the fact that models were not directly trained to predict longitudinal amyloid accumulation, our results should be interpreted with caution. Nonetheless, these results suggest that ML stratification models hold potential to identify trial candidates who are more

likely to respond to treatments, and as more clinical trial data become available, future investigations should continue to validate ML models for use within this context.

We note several key limitations which represent areas of future improvement. Firstly, due to the strict inclusion criteria employed for subject selection, the sample sizes in the present study are relatively low compared to other studies employing ML techniques for AD risk prediction. We combatted this by obtaining data from seven independent sites and including PET imaging from two tracers; nonetheless, a larger sample of preclinical AD individuals is desirable especially for developing more sophisticated ML models such as ones built upon deep learning. Secondly, utilization of the time-window approach for defining progressors meant increased heterogeneity as the time-to-progression was extended (e.g., both one-year and five-year progressors were categorized as progressors in the five-year model), which may have contributed to a more difficult classification task. Lastly, each time-to-progression model was trained independently of the rest, ignoring the constraint that predicted classifications should be consistent across time windows. Future work will explore alternate models such as time-to-event models like the survival SVM or the Mirai model for breast cancer prediction (Yala et al., 2021) which constrain predictions at multiple follow-up times to be temporally consistent.

5 Conclusion

We performed an extensive validation of machine learning for predicting future cognitive impairment in cognitively unimpaired individuals at the preclinical stage of AD. Our classifiers maintained strong generalizability across most independent testing sites as well as on unseen amyloid PET radiotracers. We further evaluated our models on the A4 clinical trial cohort and observed potential increases in statistical power to detect a secondary treatment effect, indicating potential utility for cohort enrichment. As emerging investigations of new disease-modifying therapies for AD increasingly focus on asymptomatic, preclinical populations, our findings underscore the potential applicability of ML-based patient stratification for recruiting

more homogeneous cohorts and improving statistical power for detecting treatment effects for future clinical trials.

6 Data availability

Data used in the preparation of this study are openly available and can be requested at https://www.a4studydata.org, https://adni.loni.usc.edu, https://www.mayo.edu/research/centers-programs/alzheimers-disease-research-center/research-activities/mayo-clinic-study-aging/overview, and https://sites.wustl.edu/oasisbrains. HABS data release 1.10, obtained September 2019, was used in the preparation of this article, and can be requested via https://habs.mgh.harvard.edu. A separate application process is involved for accessing PAC. Investigators interested in accessing the data should contact the PAC Coordinating Center at Johns Hopkins University for details.

SVM was implemented in scikit-learn 1.6.0 using python v3.12.8. All statistical analyses were performed in R v4.4.0. Accompanying code will be made publicly available at https://github.com/sotiraslab.

7 Acknowledgements

Acknowledgement is made to the donors of the ADR A2021042S, a program of the BrightFocus Foundation, for support of this research. The A4 Study was a secondary prevention trial in preclinical Alzheimer's disease, aiming to slow cognitive decline associated with brain amyloid accumulation in clinically normal older individuals. The A4 Study was funded by a public-private-philanthropic partnership, including funding from the National Institutes of Health-National Institute on Aging, Eli Lilly and Company, Alzheimer's Association, Accelerating Medicines Partnership, GHR Foundation, an anonymous foundation, and additional private donors, with in-kind support from Avid Radiopharmaceuticals, Cogstate, Albert Einstein College of Medicine and the Foundation for Neurologic Diseases. The companion observational Longitudinal

Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study was funded by the Alzheimer's Association and GHR Foundation. The A4 and LEARN Studies were led by Dr. Reisa Sperling at Brigham and Women's Hospital, Harvard Medical School, and Dr. Paul Aisen at the Alzheimer's Therapeutic Research Institute (ATRI) at the University of Southern California. The A4 and LEARN Studies were coordinated by ATRI at the University of Southern California, and the data are made available under the auspices of Alzheimer's Clinical Trial Consortium through the Global Research & Imaging Platform (GRIP). The complete A4 Study Team list is available on: https://www.actcinfo.org/a4-study-team-lists/. We would like to acknowledge the dedication of the study participants and their study partners who made the A4 and LEARN Studies possible. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic

Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Part of the data used in the preparation of this article were obtained from the Harvard Aging Brain Study (HABS-P01AG036694; https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fhabs.mgh.harvard.edu%2F&data=05%7C02%7Ctom.earnest%40wustl.edu%7C70bcf8c15ffb44a9848408dccc4c749f%7C4ccca3b571cd4e6d974b4d9beb96c6d6%7C0%7C0%7C638609875978514619%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=uZIOX1693oz1jyd49mvRaqaaIHC%2BXKDKPHUdotwp%2B8I%3D&reserved=0). The HABS study was launched in 2010, funded by the National Institute on Aging. and is led by principal investigators Reisa A. Sperling MD and Keith A. Johnson MD at Massachusetts General Hospital/Harvard Medical School in Boston, MA. Part of the data contained in this analysis were obtained under one of the following research grants from the National Institutes of Health to the Mayo Clinic Study of Aging (U01 AG06786, Ronald Petersen, PI) or the Mayo Alzheimer's Disease Research Center (P50 AG16574, Ronald Petersen, PI). Part of the data were provided by OASIS-3: Longitudinal Multimodal Neuroimaging (Principal Investigators: T. Benzinger, D. Marcus, J. Morris). OASIS-3 was supported by the following funding sources: NIH P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly. The Preclinical AD Consortium is supported by the National Institutes of Health (NIH), USA [grant number RF1-AG059869]. The individual studies in the consortium are funded, in part, by the following grants: U19-AG033655, P01-AG026276, RF1-AG027161 and the Australian Commonwealth Scientific Industrial Research Organization (CSIRO); as well as the National Institute on Aging Intramural Research Program.

8 CRediT authorship contribution statement

Braden Yang: Conceptualization, Investigation, Formal analysis, Methodology, Software, Visualization, Writing - original draft. **Tom Earnest**: Methodology, Software, Data curation, Writing - review & editing. **Murat Bilgel**: Methodology, Software, Data curation, Writing - review & editing. **Marilyn S. Albert**: Data curation. **Sterling C. Johnson**: Data curation. **Christos Davatzikos**: Data curation. **Guray Erus**: Data curation. **Colin L. Masters**: Data curation. **Susan M. Resnick**: Data curation, Writing - review & editing. **Michael I. Miller**: Data curation. **Arnold Bakker**: Data curation. **John C. Morris**: Data curation, Writing - review & editing. **Tammie L.S. Benzinger**: Conceptualization, Supervision, Data curation, Writing - review & editing. **Brian A. Gordon**: Conceptualization, Supervision, Writing - review & editing. **Aristeidis Sotiras**: Conceptualization, Supervision, Project administration, Funding acquisition, Writing - review & editing.

9 Funding

BY was supported by the Imaging Science Pathways NIH T32 EB014855 and BrightFocus Foundation grant ADR A2021042S. AS was supported by NIH award R01 AG067103 and BrightFocus Foundation grant ADR A2021042S.

Computations were performed using the facilities of the Washington University Research Computing and Informatics Facility, which were partially funded by NIH grants S10OD025200, 1S10RR022984-01A1 and 1S10OD018091-01. Additional support is provided by The McDonnell Center for Systems Neuroscience.

10 Competing interests

AS reported receiving personal fees from BrightFocus for serving as a grant reviewer and stock from TheraPanacea outside the submitted work. All remaining authors have no conflicting interests to report.

11 References

Abdelnour, C., Agosta, F., Bozzali, M., Fougère, B., Iwata, A., Nilforooshan, R., Takada, L.T., Viñuela, F., Traber, M., 2022. Perspectives and challenges in patient stratification in Alzheimer's disease. Alz Res Therapy 14, 112. https://doi.org/10.1186/s13195-022-01055-y

Albert, M., Soldan, A., Gottesman, R., McKhann, G., Sacktor, N., Farrington, L., Grega, M., Turner, R., Lu, Y., Li, S., Wang, M.-C., Selnes, O., 2014. Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype. Current Alzheimer Research 11, 773–784.

Ballard, C., Atri, A., Boneva, N., Cummings, J.L., Frölich, L., Molinuevo, J.L., Tariot, P.N., Raket, L.L., 2019. Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5, 164–174. https://doi.org/10.1016/j.trci.2019.04.001

Basaia, S., Agosta, F., Wagner, L., Canu, E., Magnani, G., Santangelo, R., Filippi, M., 2019. Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks. NeuroImage: Clinical 21, 101645. https://doi.org/10.1016/J.NICL.2018.101645

Birkenbihl, C., de Jong, J., Yalchyk, I., Fröhlich, H., for the Alzheimer's Disease Neuroimaging Initiative, 2024. Deep learning-based patient stratification for prognostic enrichment of clinical dementia trials. Brain Communications 6, fcae445. https://doi.org/10.1093/braincomms/fcae445

Choi, Y.S., Ngam, P.I., Lee, J.R., Hwang, D., Tan, E.-K., for the Harvard Aging Brain Study, for the Australian Imaging Biomarkers and Lifestyle Study of Aging, for the Japanese Alzheimer's Disease Neuroimaging Initiative, for the Alzheimer's Disease Neuroimaging Initiative, 2024. Deep learning-based amyloid PET harmonization to predict cognitive decline in non-demented elderly. Radiology Advances 1, umae019. https://doi.org/10.1093/radadv/umae019

Coats, M., Morris, J.C., 2005. Antecedent Biomarkers of Alzheimer's Disease: The Adult Children Study. J Geriatr Psychiatry Neurol 18, 242–244. https://doi.org/10.1177/0891988705281881

Dagley, A., LaPoint, M., Huijbers, W., Hedden, T., McLaren, D.G., Chatwal, J.P., Papp, K.V., Amariglio, R.E., Blacker, D., Rentz, D.M., Johnson, K.A., Sperling, R.A., Schultz, A.P., 2017. Harvard Aging Brain Study: Dataset and accessibility. NeuroImage, Data Sharing Part II 144, 255–258. https://doi.org/10.1016/j.neuroimage.2015.03.069

Dansson, H.V., Stempfle, L., Egilsdóttir, H., Schliep, A., Portelius, E., Blennow, K., Zetterberg, H., Johansson, F.D., for the Alzheimer's Disease Neuroimaging Initiative (ADNI), 2021. Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. Alzheimer's Research & Therapy 13, 151. https://doi.org/10.1186/s13195-021-00886-5

Donohue, M.C., Langford, O., Insel, P.S., van Dyck, C.H., Petersen, R.C., Craft, S., Sethuraman, G., Raman, R., Aisen, P.S., Initiative, F. the A.D.N., 2023. Natural cubic splines for the analysis of Alzheimer's clinical trials. Pharmaceutical Statistics 22, 508–519. https://doi.org/10.1002/pst.2285

Donohue, M.C., Sperling, R.A., Salmon, D.P., Rentz, D.M., Raman, R., Thomas, R.G., Weiner, M., Aisen, P.S., 2014. The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline. JAMA Neurology 71, 961–970. https://doi.org/10.1001/JAMANEUROL.2014.803

Doshi, J., Erus, G., Ou, Y., Resnick, S.M., Gur, R.C., Gur, R.E., Satterthwaite, T.D., Furth, S., Davatzikos, C., 2016. MUSE: MUlti-atlas region Segmentation utilizing Ensembles of

registration algorithms and parameters, and locally optimal atlas selection. NeuroImage 127, 186–195. https://doi.org/10.1016/j.neuroimage.2015.11.073

Dyck, C.H. van, Swanson, C.J., Aisen, P., Bateman, R.J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L.D., Iwatsubo, T., 2023. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine 388, 9–21. https://doi.org/10.1056/NEJMoa2212948

Ezzati, A., Abdulkadir, A., Jack, C.R., Thompson, P.M., Harvey, D.J., Truelove-Hill, M., Sreepada, L.P., Davatzikos, C., Lipton, R.B., 2021. Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia. Alzheimer's & Dementia 17, 1855–1867. https://doi.org/10.1002/ALZ.12491

Fan, S., Ponisio, M.R., Xiao, P., Ha, S.M., Chakrabarty, S., Lee, J.J., Flores, S., LaMontagne, P., Gordon, B., Raji, C.A., Marcus, D.S., Nazeri, A., Ances, B.M., Bateman, R.J., Morris, J.C., Benzinger, T.L.S., Sotiras, A., Haller, S., Atzen, S., 2024. AmyloidPETNet: Classification of Amyloid Positivity in Brain PET Imaging Using End-to-End Deep Learning. Radiology 311, e231442. https://doi.org/10.1148/radiol.231442

Fowler, C., Rainey-Smith, S.R., Bird, S., Bomke, J., Bourgeat, P., Brown, B.M., Burnham, S.C., Bush, A.I., Chadunow, C., Collins, S., Doecke, J., Doré, V., Ellis, K.A., Evered, L., Fazlollahi, A., Fripp, J., Gardener, S.L., Gibson, S., Grenfell, R., Harrison, E., Head, R., Jin, L., Kamer, A., Lamb, F., Lautenschlager, N.T., Laws, S.M., Li, Q.-X., Lim, L., Lim, Y.Y., Louey, A., Macaulay, S.L., Mackintosh, L., Martins, R.N., Maruff, P., Masters, C.L., McBride, S., Milicic, L., Peretti, M., Pertile, K., Porter, T., Radler, M., Rembach, A., Robertson, J., Rodrigues, M., Rowe, C.C., Rumble, R., Salvado, O., Savage, G., Silbert, B., Soh, M., Sohrabi, H.R., Taddei, K., Taddei, T., Thai, C., Trounson, B., Tyrrell, R., Vacher, M., Varghese, S., Villemagne, V.L., Weinborn, M., Woodward, M., Xia, Y., Ames, D., 2021. Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. Journal of Alzheimer's Disease Reports 5, 443–468. https://doi.org/10.3233/ADR-210005

Gladstein, S., Yang, L., Wooten, D., Huang, X., Comley, R., Guo, Q., Initiative, the A.D.N., 2025. Machine learning–enhanced screening funnel for clinical trials in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 11, e70084. https://doi.org/10.1002/trc2.70084

Grueso, S., Viejo-Sobera, R., 2021. Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer's disease dementia: a systematic review. Alz Res Therapy 13, 162. https://doi.org/10.1186/s13195-021-00900-w

Haufe, S., Meinecke, F., Görgen, K., Dähne, S., Haynes, J.-D., Blankertz, B., Bießmann, F., 2014. On the interpretation of weight vectors of linear models in multivariate neuroimaging. NeuroImage 87, 96–110. https://doi.org/10.1016/j.neuroimage.2013.10.067

Huang, L.-K., Chao, S.-P., Hu, C.-J., 2020. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 27, 18. https://doi.org/10.1186/s12929-019-0609-7

Jack, C.R., Holtzman, D.M., 2013. Biomarker Modeling of Alzheimer's Disease. Neuron 80, 1347–1358. https://doi.org/10.1016/j.neuron.2013.12.003

Jack Jr., C.R., Andrews, J.S., Beach, T.G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., Molinuevo, J.L., Okonkwo, O.C., Pani, L., Rafii, M.S., Scheltens, P., Siemers, E., Snyder, H.M., Sperling, R., Teunissen, C.E., Carrillo, M.C., 2024. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia 20, 5143–5169. https://doi.org/10.1002/alz.13859

Johnson, S.C., Koscik, R.L., Jonaitis, E.M., Clark, L.R., Mueller, K.D., Berman, S.E., Bendlin, B.B., Engelman, C.D., Okonkwo, O.C., Hogan, K.J., Asthana, S., Carlsson, C.M., Hermann, B.P., Sager, M.A., 2018. The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 10, 130–142. https://doi.org/10.1016/j.dadm.2017.11.007

Jutten, R.J., Sikkes, S.A.M., Flier, W.M.V. der, Scheltens, P., Visser, P.J., Tijms, B.M., Initiative, for the A.D.N., 2021. Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. Neurology 96, e2673–e2684. https://doi.org/10.1212/WNL.0000000000012022

Karaman, B.K., Mormino, E.C., Sabuncu, M.R., Initiative, for the A.D.N., 2022. Machine learning based multi-modal prediction of future decline toward Alzheimer's disease: An empirical study. PLOS ONE 17, e0277322. https://doi.org/10.1371/journal.pone.0277322

Kim, C.K., Lee, Y.R., Ong, L., Gold, M., Kalali, A., Sarkar, J., 2022. Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures. Journal of Alzheimer's Disease 87, 83–100. https://doi.org/10.3233/JAD-215699

Klunk, W.E., Koeppe, R.A., Price, J.C., Benzinger, T.L., Devous Sr., M.D., Jagust, W.J., Johnson, K.A., Mathis, C.A., Minhas, D., Pontecorvo, M.J., Rowe, C.C., Skovronsky, D.M., Mintun, M.A., 2015. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's & Dementia 11, 1-15.e4. https://doi.org/10.1016/j.jalz.2014.07.003

Laakso, M.P., Soininen, H., Partanen, K., Helkala, E.-L., Hartikainen, P., Vainio, P., Hallikainen, M., Hänninen, T., Riekkinen Sr, P.J., 1995. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: Correlation with memory functions. J Neural Transm Gen Sect 9, 73–86. https://doi.org/10.1007/BF02252964

LaMontagne, P.J., Benzinger, T.LS., Morris, J.C., Keefe, S., Hornbeck, R., Xiong, C., Grant, E., Hassenstab, J., Moulder, K., Vlassenko, A.G., Raichle, M.E., Cruchaga, C., Marcus, D., 2019. OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease. medRxiv 2019.12.13.19014902. https://doi.org/10.1101/2019.12.13.19014902

Landau, S.M., Horng, A., Jagust, W.J., For the Alzheimer's Disease Neuroimaging Initiative, 2018. Memory decline accompanies subthreshold amyloid accumulation. Neurology 90, e1452–e1460. https://doi.org/10.1212/WNL.0000000000005354

Landau, S.M., Thomas, B.A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun, M., Pontecorvo, M., Baker, S.L., Jagust, W.J., the Alzheimer's Disease Neuroimaging Initiative, 2014. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41, 1398–1407. https://doi.org/10.1007/s00259-014-2753-3

Linn, K.A., Gaonkar, B., Satterthwaite, T.D., Doshi, J., Davatzikos, C., Shinohara, R.T., 2016. Control-group feature normalization for multivariate pattern analysis of structural MRI data using the support vector machine. NeuroImage 132, 157–166. https://doi.org/10.1016/J.NEUROIMAGE.2016.02.044

Mathotaarachchi, S., Pascoal, T.A., Shin, M., Benedet, A.L., Kang, M.S., Beaudry, T., Fonov, V.S., Gauthier, S., Rosa-Neto, P., 2017. Identifying incipient dementia individuals using machine learning and amyloid imaging. Neurobiology of Aging 59, 80–90. https://doi.org/10.1016/J.NEUROBIOLAGING.2017.06.027

Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., Hansson, O., 2019. Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurol 76, 1319–1329. https://doi.org/10.1001/jamaneurol.2019.2214

Misra, C., Fan, Y., Davatzikos, C., 2009. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: Results from ADNI. NeuroImage 44, 1415–1422. https://doi.org/10.1016/j.neuroimage.2008.10.031

Morris, J.C., 1997. Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type. International Psychogeriatrics 9, 173–176. https://doi.org/10.1017/S1041610297004870

Mungas, D., Reed, B.R., Jagust, W.J., DeCarli, C., Mack, W.J., Kramer, J.H., Weiner, M.W., Schuff, N., Chui, H.C., 2002. Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology 59, 867–873. https://doi.org/10.1212/WNL.59.6.867

Nallapu, B.T., Petersen, K.K., Qian, T., Demirsoy, I., Ghanbarian, E., Davatzikos, C., Lipton, R.B., Ezzati, A., for the Alzheimer's Disease Neuroimaging Initiative, 2025. A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials. Neurology 104, e213490. https://doi.org/10.1212/WNL.0000000000213490

Nestor, S.M., Rupsingh, R., Borrie, M., Smith, M., Accomazzi, V., Wells, J.L., Fogarty, J., Bartha, R., 2008. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain 131, 2443–2454. https://doi.org/10.1093/brain/awn146

Parent, C., Rousseau, L.-S., Predovan, D., Duchesne, S., Hudon, C., 2023. Longitudinal association between ß-amyloid accumulation and cognitive decline in cognitively healthy older adults: A systematic review. Aging Brain 3, 100074. https://doi.org/10.1016/j.nbas.2023.100074

Pascoal, T.A., Therriault, J., Mathotaarachchi, S., Kang, M.S., Shin, M., Benedet, A.L., Chamoun, M., Tissot, C., Lussier, F., Mohaddes, S., Soucy, J.P., Massarweh, G., Gauthier, S., Rosa-Neto, P., 2020. Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 12, e12037. https://doi.org/10.1002/DAD2.12037

Pfeil, J., Hoenig, M.C., Doering, E., van Eimeren, T., Drzezga, A., Bischof, G.N., 2021. Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease. Neurobiology of Aging 106, 119–129. https://doi.org/10.1016/J.NEUROBIOLAGING.2021.06.014

Price, J.L., Morris, J.C., 1999. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Annals of Neurology 45, 358–368. https://doi.org/10.1002/1531-8249(199903)45:3%253C358::AID-ANA12%253E3.0.CO;2-X

Resnick, S.M., Goldszal, A.F., Davatzikos, C., Golski, S., Kraut, M.A., Metter, E.J., Bryan, R.N., Zonderman, A.B., 2000. One-year Age Changes in MRI Brain Volumes in Older Adults. Cereb Cortex 10, 464–472. https://doi.org/10.1093/cercor/10.5.464

Roberts, R.O., Geda, Y.E., Knopman, D.S., Cha, R.H., Pankratz, V.S., Boeve, B.F., Ivnik, R.J., Tangalos, E.G., Petersen, R.C., Rocca, W.A., 2008. The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics. Neuroepidemiology 30, 58–69. https://doi.org/10.1159/000115751

Samper-González, J., Burgos, N., Bottani, S., Fontanella, S., Lu, P., Marcoux, A., Routier, A., Guillon, J., Bacci, M., Wen, J., Bertrand, A., Bertin, H., Habert, M.O., Durrleman, S., Evgeniou, T., Colliot, O., 2018. Reproducible evaluation of classification methods in Alzheimer's disease: Framework and application to MRI and PET data. NeuroImage 183, 504–521. https://doi.org/10.1016/J.NEUROIMAGE.2018.08.042

Sims, J.R., Zimmer, J.A., Evans, C.D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A.M., Shcherbinin, S., Wang, H., Monkul Nery, E.S., Collins, E.C., Solomon, P., Salloway, S., Apostolova, L.G., Hansson, O., Ritchie, C., Brooks, D.A., Mintun, M., Skovronsky, D.M., TRAILBLAZER-ALZ 2 Investigators, 2023. Donanemab in Early Symptomatic Alzheimer

Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330, 512–527. https://doi.org/10.1001/jama.2023.13239

Small, G.W., Siddarth, P., Kepe, V., Ercoli, L.M., Burggren, A.C., Bookheimer, S.Y., Miller, K.J., Kim, J., Lavretsky, H., Huang, S.-C., Barrio, J.R., 2012. Prediction of Cognitive Decline by Positron Emission Tomography of Brain Amyloid and Tau. Arch Neurol 69, 215–222. https://doi.org/10.1001/archneurol.2011.559

Smith, S.M., Jenkinson, M., Woolrich, M.W., Beckmann, C.F., Behrens, T.E.J., Johansen-Berg, H., Bannister, P.R., De Luca, M., Drobnjak, I., Flitney, D.E., Niazy, R.K., Saunders, J., Vickers, J., Zhang, Y., De Stefano, N., Brady, J.M., Matthews, P.M., 2004. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage, Mathematics in Brain Imaging 23, S208–S219. https://doi.org/10.1016/j.neuroimage.2004.07.051

Sperling, R.A., Donohue, M.C., Raman, R., Rafii, M.S., Johnson, K., Masters, C.L., Dyck, C.H. van, Iwatsubo, T., Marshall, G.A., Yaari, R., Mancini, M., Holdridge, K.C., Case, M., Sims, J.R., Aisen, P.S., 2023. Trial of Solanezumab in Preclinical Alzheimer's Disease. New England Journal of Medicine 389, 1096–1107. https://doi.org/10.1056/NEJMoa2305032

Sperling, R.A., Rentz, D.M., Johnson, K.A., Karlawish, J., Donohue, M., Salmon, D.P., Aisen, P., 2014. The A4 study: Stopping AD before symptoms begin? Science Translational Medicine 6. https://doi.org/10.1126/SCITRANSLMED.3007941/ASSET/1A7D4501-F70E-47E3-B98C-C19B558DDE40/ASSETS/GRAPHIC/6228FS13-F1.JPEG

Su, Y., Flores, S., Wang, G., Hornbeck, R.C., Speidel, B., Joseph-Mathurin, N., Vlassenko, A.G., Gordon, B.A., Koeppe, R.A., Klunk, W.E., Jack Jr., C.R., Farlow, M.R., Salloway, S., Snider, B.J., Berman, S.B., Roberson, E.D., Brosch, J., Jimenez-Velazques, I., van Dyck, C.H., Galasko, D., Yuan, S.H., Jayadev, S., Honig, L.S., Gauthier, S., Hsiung, G.-Y.R., Masellis, M., Brooks, W.S., Fulham, M., Clarnette, R., Masters, C.L., Wallon, D., Hannequin, D., Dubois, B., Pariente, J., Sanchez-Valle, R., Mummery, C., Ringman, J.M., Bottlaender, M., Klein, G., Milosavljevic-Ristic, S., McDade, E., Xiong, C., Morris, J.C., Bateman, R.J., Benzinger, T.L.S., 2019. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 11, 180–190. https://doi.org/10.1016/j.dadm.2018.12.008

Swanson, C.J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R.Y.K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., Reyderman, L., Berry, D.A., Berry, S., Gordon, R., Kramer, L.D., Cummings, J.L., 2021. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alz Res Therapy 13, 80. https://doi.org/10.1186/s13195-021-00813-8

Tam, A., Laurent, C., Gauthier, S., Dansereau, C., 2022. Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials. The Journal of Prevention of Alzheimer's Disease 9, 400–409. https://doi.org/10.14283/jpad.2022.49

Tustison, N.J., Avants, B.B., Cook, P.A., Zheng, Y., Egan, A., Yushkevich, P.A., Gee, J.C., 2010. N4ITK: Improved N3 Bias Correction. IEEE Transactions on Medical Imaging 29, 1310–1320. https://doi.org/10.1109/TMI.2010.2046908

Villemagne, V.L., Mulligan, R.S., Pejoska, S., Ong, K., Jones, G., O'Keefe, G., Chan, J.G., Young, K., Tochon-Danguy, H., Masters, C.L., Rowe, C.C., 2012. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 39, 983–989. https://doi.org/10.1007/s00259-012-2088-x

Wang, C., Tachimori, H., Yamaguchi, H., Sekiguchi, A., Li, Y., Yamashita, Y., 2024. A multimodal deep learning approach for the prediction of cognitive decline and its effectiveness in clinical trials for Alzheimer's disease. Transl Psychiatry 14, 1–11. https://doi.org/10.1038/s41398-024-02819-w

Wolz, R., Schwarz, A.J., Gray, K.R., Yu, P., Hill, D.L.G., For the Alzheimer's Disease Neuroimaging Initiative, 2016. Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology 87, 1235–1241. https://doi.org/10.1212/WNL.0000000000003126

Yala, A., Mikhael, P.G., Strand, F., Lin, G., Smith, K., Wan, Y.-L., Lamb, L., Hughes, K., Lehman, C., Barzilay, R., 2021. Toward robust mammography-based models for breast cancer risk. Science Translational Medicine 13, eaba4373. https://doi.org/10.1126/scitranslmed.aba4373